Avisi in the Press
MedTech Innovator Accelerator
A subset of 25 early-stage companies will participate in MedTech Innovator’s award-winning Accelerator program, in which medtech startups are matched with senior industry leaders to receive in-depth, customized mentorship and support. With a competitive 3% acceptance rate, the selection process for this year’s program set a high bar for applicants. Together with the senior leadership teams of its corporate partners and over 200 industry judges, MedTech Innovator traveled to evaluate over 150 candidates in person out of over 800 applications from 34 countries and 45 U.S. states.
The inaugural cohort of JPOD resident companies, which J&J will support in various capacities from concept to commercialization. The seven early-stage startups are treating glaucoma, reconstructing peripheral nerves, developing brain stimulation therapies, and much, much more.
“The Future of Entrepreneurship is Students”
Avisi Technologies entered the Y-Prize, which encourages students to find commercialization opportunities for Penn research, educated themselves about the nanoscale technology in question, and won the competition.
Best of the Best
“Each year we are impressed with the companies that win best in show over the course of the year and we have continued to be impressed by the progress made by Avisi even since their October win,” commented Yaniv Sneor, MABA co-founder and president of Blue Cactus Consulting. “They continued to evolve their presentation and demonstrated the spirit of these events by rounding out an already compelling story, which has the potential to provide a solution for millions of people suffering from glaucoma.”
Avisi Technologies is now a member of JLABS, the premier life science incubator empowering and enabling innovators to deliver life-enhancing health and wellness solutions to people around the globe.
VisiPlate, Avisi’s nanoscale ocular implant, has the potential to transform glaucoma treatment and vision-loss prevention.
Best in Sho
Mid-Atlantic Bio Angels (MABA) announces today that Avisi Technologies, LLC, which develops an eye implant for glaucoma, was named “Best in Show” by the audience at MABA’s 1st Pitch Life Science event held on October 16, 2018 at the Cira Centre in Philadelphia.
Each student’s unique perspective, such as Jiang’s experience working in pharmaceutical companies, Kao’s knowledge of materials science engineering, and Battu’s understanding of need-finding through past startup experience, allowed them to take a very research-focused view to leverage this novel nanotechnology in the human body.
In addition to being a home-base for Penn laboratories and numerous companies, including Avisi Technologies, a recent President’s Innovation Prize winner, the Pennovation Center serves as a hub for an “innovation ecosystem”.
In front of a standing-room-only crowd in the Singh Center’s Glandt Forum this week, four teams made their pitches for how to turn technology developed by Penn Engineers into the next big thing.
Each year, the Mack Institute, Penn Engineering, Penn Wharton Entrepreneurship, and the Penn Center for Innovation come together for the invention competition known as the Y-Prize. Unlike the XPRIZE, where competitors come up with novel technologies to solve a particular problem, the Y-Prize starts with the technologies and challenges entrants to find commercial applications they are particularly suited for.
University of Pennsylvania President Amy Gutmann today announced the recipients of the 2018 President’s Engagement Prizes and President’s Innovation Prize. Awarded annually, the Prizes provide $100,000 in funding for Penn seniors to design and undertake post-graduation projects that make a positive, lasting difference in the world.
Wharton VIP- X
VIP-X is an intense accelerator program for Penn startups that are ready to launch.
Meet some of our Fall 2017 members.
Interview with Brandon Kao, nanotechnology start-up co-founder of Avisi Technologies
“Working on VisiPlate has presented me with different types of challenges that helped me gain a more general knowledge of product development”